LVW Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

LVW Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-487	Closed	-$220K	–	205
2020 Q2	$220K	Buy	+487	New	+$215K	0.05%	180

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

LVW Advisors's BIO Position: Q3 2020 in Review

LVW Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2020, closing a stake of 487 shares — an estimated $220K sold.

LVW Advisors first reported a position in BIO in Q2 2020 and held it in 1 quarter. The position peaked at $220K in Q2 2020. 479 funds tracked by Wall St. Rank hold BIO as of Q3 2020.

LVW Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2020 after selling out during the quarter.
LVW Advisors sold 487 Bio-Rad Laboratories Class A shares in Q3 2020, an estimated $220K.
LVW Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 1 quarter.
LVW Advisors's Bio-Rad Laboratories Class A position peaked at $220K in Q2 2020.
479 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2020.

Based on LVW Advisors's 13F filing for Q3 2020, filed 29 Oct 2020.